---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-009312"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:21:39.724794+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# The Oncology Institute issues FY2022 results and 2023 guidance; specific numbers not available in filing text

## Summary
- Slide presentation furnished as Exhibit 99.1 includes financial results for Q4 and FY2022.
- Presentation also provides business update and guidance for the year ending December 31, 2023.
- Exact revenue, EPS, or other financial figures are not disclosed in the provided filing excerpt.

## SEC filing metadata
- accession: 0001628280-23-009312
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828023009312/0001628280-23-009312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828023009312/toi-20230327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-009312
- JSON: https://secwatch.observer/filing/0001628280-23-009312.json
- Plain text: https://secwatch.observer/filing/0001628280-23-009312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.